Comprender la promociÃ³n farmacÃ©utica y responder a ella - Multiple ...

More documents

Recommendations

Info

84 | Comprender la promoción farmacéutica y responder a ella - una guía prácticaMaestri E, Furlani G, Suzzi F et al. (2000). So much time for so little: Italy’s pharmaceutical industry and doctors'information needs. British Medical Journal, 320:55.McCormick BB, Tomlinson G, Brill-Edwards P et al. (2001). Effect of restricting contact between pharmaceuticalcompany representatives and internal medicine residents on post training attitudes and behavior. Journal of theAmerican Medical Association, 286:1994-1999.Merck (2001). 3T99 refocus for Vioxx.Mintzes B (2005). Educational initiatives for medical and pharmacy students about drug promotion: An internationalcross-sectional survey. (Puede verse un resumen en español en:http://www.boletinfarmacos.org/042007/investigacionesA.asp, Ginebra, Organización Mundial de la Salud y AcciónInternacional para la Salud).Moghimi Y (2006). The “PharmFree” campaign: Educating medical students about industry influence. PublicLibrary of Science Medicine, 3(1):e30.Muijrers PE, Grol RP, Sijbrandij J et al. (2005). Differences in prescribing between GPs: impact of the cooperationwith pharmacists and impact of visits from pharmaceutical industry representatives. Family Practice 22(6):624-30 (http://www.fampra.oxfordjournals.org/cgi/content/full/22/6/624, se tuvo acceso el 17 de abril de 2009).Norris P, Herxheimer A, Lexchin J et al. (2005). Drug promotion: what we know, what we have yet to learn.Ginebra, Organización Mundial de la Salud y Acción Internacional para la Salud.O’Keefe DJ (2002). Persuasion: theory & research. 2nd ed. Thousand Oaks, California, Sage.Oldani MJ (2004). Thick prescriptions: toward an interpretation of pharmaceutical sales practices. MedicalAnthropology Quarterly, 8(3):325-356.Oxman AD, Thomson MA, Davis DA et al. (1995). No magic bullets: a systematic review of 102 trials of interventionsto improve professional practice. Canadian Medical Association Journal, 153:1423-1431.Peay MY, Peay ER (1988). The role of commercial sources in the adoption of a new drug. Social Science andMedicine, 26(12):1183-1189.Prosser H, Almond S, Walley T (2003). Influences on GPs’ decisions to prescribe new drugs – the importance ofwho says what. Family Practice, 20(1):61-68.Prosser H and Walley T (2003). New drug uptake: qualitative comparison of high and low prescribing GPs’ attitudesand approach. Family Practice 20(5):583-91 (http://www.fampra.oxfordjournals.org/cgi/content/full/20/5/583, setuvo acceso el 17 de abril de 2009).Relman S (2001). Separating continuing medical education from pharmaceutical marketing. Journal of the AmericanMedical Association, 285(15):2009-2012.Republic of South Africa (1965) Medicines and related substances control amendment act (Act 101 of 1965) asamended (http://www.mccza.com, se tuvo acceso el 17 de abril de 2009).Rogers WA, Mansfield PR, Braunack-Mayer AJ et al. (2004). The ethics of pharmaceutical industry relationshipswith medical students. Medical Journal of Australia, 180:411-414.Roughead EE, Gilbert AL, Harvey KJ (1998). Self-regulatory codes of conduct: are they effective in controllingpharmaceutical representatives' presentations to general medical practitioners? International Journal of HealthServices, 28(2):269-279.Roughead EE, Harvey KJ, Gilbert AL (1998a). Commercial detailing techniques used by pharmaceutical representativesto influence prescribing. Australia and New Zealand Journal of Medicine, 28(3):306-310.Sandberg WS, Carlos R, Sandberg EH et al. (1997). The effect of educational gifts from pharmaceutical firms onmedical students’ recall of company names or products. Academic Medicine, 72:916-918.
Capítulo 4 - Los visitadores médicos | 85Saul S (2005). Gimme an Rx! Cheerleaders pep up drug sales. New York Times, 28 de noviembre(http://www.nytimes.com/2005/11/28/business/28cheer.html?ei=5089&en=1f0c2de786b66953&ex=1290834000&partner=rssyahoo&emc=rss&pagewanted=all, se tuvo acceso el 17 de abril de 2009).Schafer A (2004). Biomedical conflicts of interest: a defence of the sequestration thesis – learning from the casesof Nancy Olivieri and David Healy. Journal of Medical Ethics, 30:8-24.Stafford RS, Furberg CD, Finkelstein SN et al. (2004). Impact of clinical trial results on national trends in alphablockerprescribing, 1996-2002. Journal of the American Medical Association 291(1):54-62 (http://www.jama.amaassn.org/cgi/content/full/291/1/54,se tuvo acceso el 17 de abril de 2009).Steinman MA, Harper GM, Chren MM et al. (2007). Charactertistics and impact of drug detailing for gabapentin.PLoS Med. Apr;4(4):e134 (http://www.medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040134&ct=1, se tuvo acceso el 17 de abril de 2009).Steinman MA, Shlipak MG, McPhee SJ (2001). Of principles and pens: attitudes and practices of medicine housestafftowards pharmaceutical industry promotions. American Journal of Medicine, 110: 551-557.Strang D, Gagnon M, Mollow W et al. (1996). National survey on the attitudes of Canadian physicians towardsdrug-detailing by pharmaceutical representatives. Annals of the Royal College of Physicians and Surgeons ofCanada, 29:474-478.Sweet M (2003). Gabapentin documents raise concerns about off-label promotion and prescribing. AustralianPrescriber, 26:18-19.Wazana A (2000). Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of the AmericanMedical Association, 283: 373-380.Westfall JM, McCabe J, Nicholas RA (1997). Personal use of drug samples by physicians and office staff. Journalof the American Medical Association, 278(2):141-143.Wilkes MS, Hoffman JR (2001). An innovative approach to educating medical students about pharmaceuticalpromotion. Academic Medicine, 76:1271-1277.World Health Organization (1988). Ethical criteria for medicinal drug promotion (Existe versión en español:Criterios Éticos para la Promoción de Medicamentos, OMS, Ginebra, 1988. Disponible en:http://archives.who.int/tbs/promo/whozip09s.pdf).Ziegler MG, Lew P, Singer BC (1995). The accuracy of drug information from pharmaceutical sales representatives.Journal of the American Medical Association, 273(16):1296-1298.Zipkin DA, Steinman MA (2005). Interactions between pharmaceutical representatives and doctors in training. Athematic review. Journal of General Internal Medicine, 2(34):777-786.
Page 3 and 4:
XXXXXComprenderla promoción farmac
Page 5:
ContenidoPrefacio .................
Page 9 and 10:
Reconocimientos | 5ReconocimientosA
Page 11 and 12:
Reconocimientos | 7Traductores:Al r
Page 13 and 14:
Siglas y acrónimos | 9Siglas y acr
Page 15 and 16:
Capítulo 1 - La promoción farmac
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Capítulo 2 - Técnicas que influye
Page 33 and 34:
Page 35 and 36:
Page 37 and 38: Capítulo 2 - Técnicas que influye
Page 47 and 48: Capítulo 3 - Análisis de los anun
Page 57 and 58: Referencias en los anunciosCapítul
Page 69 and 70: Capítulo 4 - Los visitadores médi
Page 87: Capítulo 4 - Los visitadores médi
Page 91 and 92: Capítulo 5 - Promoción a los cons
Page 117 and 118: Capítulo 6 - Aprender a no bailar
Page 137 and 138: Capítulo 7Capítulo 7 - La regulac
Page 139 and 140:
Capítulo 7 - La regulación de la
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Capítulo 8 - Usar información imp
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Capítulo 9Capítulo 9 - La promoci
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 196:
El papel de médicos y farmacéutic
show all

Comprender la promociÃ³n farmacÃ©utica y responder a ella - Multiple ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?